Sergey Yagoda, PhD, MD

LATITUDE: Long-Acting Antipsychotic Treatments in Community Telepsychiatry: Knowledge, Attitudes, and Perceived Barriers

Abstract: Background/Objective: The South Carolina Department of Mental Health instituted a Community Telepsychiatry Program (CTP) to increase patient access to mental health practitioner...

Sergey Yagoda , PhD, MD;

01/19/2023

A Combination of Olanzapine and Samidorphan Has No Clinically Relevant Effect on QT Prolongation Up to Supratherapeutic Doses

Background: ALKS 3831, a combination of olanzapine and samidorphan (OLZ/SAM) in development for schizophrenia, is intended to mitigate olanzapine-associated weight gain. This thorough QT ...

Lisa L. von Moltke , MD, FCPP;

Lei Sun , PhD;

Sergey Yagoda , PhD, MD;

Hongqu Xue , PhD;

Randy Brown , MS;

Narinder Nangia , PhD;

Bhaskar Rege , PhD, BPharm;

Borje Darpo , MD, PhD;

David McDonnell , MD;

11/22/2019

Randomized, Double-Blind, Active-Controlled Study of Starting Aripiprazole Lauroxil With 1-Day Initiation in Acutely Ill Patients With Schizophrenia

Objective: Evaluate efficacy and safety of a 2-month dose of aripiprazole lauroxil (AL) with a 1-day initiation regimen during hospitalization for an acute exacerbation of schizophrenia. ...

Sergey Yagoda , PhD, MD;

David Walling , PhD, CNS, MD;

Jelena Kunovac , MD;

Amy Claxton , PhD;

Yangchun Du , PhD;

Peter J. Weiden , MD, PhD;

11/22/2019

A Phase 3, Multicenter Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Olanzapine/Samidorphan in Patients With Schizophrenia

Background: ALKS 3831, a combination of olanzapine and samidorphan (OLZ/SAM), is in development for the treatment of schizophrenia and is intended to provide the antipsychotic efficacy of...

Christina Arevalo , MS;

Sergey Yagoda , PhD, MD;

Christine Graham , PhD;

Yangsong Cheng , PhD;

Adam Simmons , MPH;

David McDonnell , MD;

11/22/2019